Larry Stitt
Robarts Research Institute
7 Papers
Larry Stitt is an academic researcher from Robarts Research Institute. The author has contributed to research in topics: Randomized controlled trial & Immunosuppression. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna,Reena Khanna,Brian Bressler,Barrett G. Levesque,Barrett G. Levesque,Guangyong Zou,Guangyong Zou,Larry Stitt,Gordon R. Greenberg,Remo Panaccione,Alain Bitton,Pierre Paré,Severine Vermeire,Geert R. D'Haens,Geert R. D'Haens,Donald G. MacIntosh,William J. Sandborn,William J. Sandborn,Allan Donner,Allan Donner,Margaret K. Vandervoort,Joan C. Morris,Brian G. Feagan,Brian G. Feagan +23 more
TL;DR: Although ECI was not more effective than conventional management for controlling Crohn's disease symptoms, the risk of major adverse outcomes was lower and the latter finding should be considered hypothesis-generating for future trials.
414
The development of a magnetic resonance imaging index for fistulising Crohn's disease.
Mark A Samaan,Carl A. J. Puylaert,Barrett G. Levesque,Guangyong Zou,Larry Stitt,Stuart A. Taylor,Lisa M. Shackelton,Margaret K. Vandervoort,Reena Khanna,Cynthia Santillan,Jordi Rimola,Pieter Hindryckx,C. Y. Nio,W J Sandborn,G. D'Haens,Brian G. Feagan,Vipul Jairath,Jaap Stoker +17 more
TL;DR: The Van Assche index is the most commonly used MRI fistula index and is the gold standard for assessment of perianal fistulising Crohn's disease.
Reliability of histologic assessment in patients with eosinophilic oesophagitis.
Marijn J. Warners,C. A. Ambarus,Arjan Bredenoord,Joanne Verheij,Gregory Y. Lauwers,J. C. Walsh,David A. Katzka,Sigrid Nelson,T. van Viegen,Glenn T. Furuta,Sandeep Gupta,Larry Stitt,Guangyong Zou,Claire E Parker,Lisa M. Shackelton,G. R. D`Haens,W J Sandborn,Evan S. Dellon,Brian G. Feagan,Margaret H. Collins,Vipul Jairath,Rish K. Pai +21 more
TL;DR: The validity of the eosinophilic oesophagitis histologic scoring system (EoEHSS) has been demonstrated, but only preliminary reliability data exist.
51
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
G. D'Haens,W J Sandborn,Guangyong Zou,Larry Stitt,Paul Rutgeerts,D. Gilgen,Vipul Jairath,Pieter Hindryckx,Lisa M. Shackelton,Margaret K. Vandervoort,Claire E Parker,C. Muller,Rish K. Pai,O. Levchenko,Y. Marakhouski,M. Horynski,E. Mikhailova,N. Kharchenko,S. Pimanov,Brian G. Feagan +19 more
TL;DR: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis.
43
Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.
Siddharth Singh,Vipul Jairath,Larry Stitt,Guangyong Zou,Guangyong Zou,Reena Khanna,Parambir S. Dulai,W J Sandborn,Brian G. Feagan,Brian G. Feagan +9 more
TL;DR: Although this study is one of the largest evaluating impacts of early combined immunosuppression versus conventional manage‐ ment over a 2‐year period, it was not adequately powered to address safety of different therapies.